Treatment of Acute Respiratory Distress Syndrome with Recombinant Surfactant Protein C Surfactant
- 1 June 2003
- journal article
- clinical trial
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 167 (11), 1562-1566
- https://doi.org/10.1164/rccm.200207-782oc
Abstract
We performed a phase I/II trial in North America of a recombinant surfactant protein C-based surfactant (Venticute) as treatment for the acute respiratory distress syndrome. Patients were prospectively randomized to receive either standard therapy or standard therapy plus one of two doses of exogenous surfactant given four times over 24 hours. Surfactant administration was well tolerated. No significant treatment benefit was associated with surfactant treatment. Bronchoalveolar lavage of treated patients at 48 hours reflected the presence of exogenous surfactant components, did not show evidence of improved surface tension lowering function, and had interleukin-6 concentrations that were significantly lower than control group values, consistent with an antiinflammatory treatment effect. The presence of exogenous surfactant was not detected in lavage fluid obtained at 120 hours. Future studies might rationally employ larger surfactant doses and a more prolonged dosing schedule.This publication has 28 references indexed in Scilit:
- Surfactant Proteins A and D and Pulmonary Host DefenseAnnual Review of Physiology, 2001
- Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress SyndromeThe New England Journal of Medicine, 2000
- Effect on the Duration of Mechanical Ventilation of Identifying Patients Capable of Breathing SpontaneouslyThe New England Journal of Medicine, 1996
- Calf's lung surfactant extract in acute hypoxemic respiratory failure in childrenCritical Care Medicine, 1996
- Aerosolized Surfactant in Adults with Sepsis-Induced Acute Respiratory Distress SyndromeThe New England Journal of Medicine, 1996
- Pulmonary Surfactant TherapyThe New England Journal of Medicine, 1993
- Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome.JCI Insight, 1991
- Surfactant for adults with respiratory failureThe Lancet, 1990
- Elastase and alpha 1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome. Role of inflammation in the pathogenesis of bronchopulmonary dysplasia.JCI Insight, 1983
- Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol.JCI Insight, 1982